Apexigen (APGN) Stock Price, News & Analysis

Company Overview

Apexigen, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. Apexigen, Inc. was founded in 2010 and is headquartered in San Carlos, California.

Key Stats

• Today's Range: $0.39 to $0.39
• 50-Day Range: $0.36 to $0.44
• 52-Week Range: $0.33 to $8.28
• Volume: N/A
• Average Volume: 967,731 shs
• Market Capitalization: $9.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

APGN Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Apexigen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Apexigen investors own include Sunworks (SUNW), Applied DNA Sciences (APDN), Ginkgo Bioworks (DNA), Avino Silver & Gold Mines (ASM), Ambrx Biopharma (AMAM) and Avalo Therapeutics (AVTX).

Company Calendar

• Today: 8/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:APGN
• CIK: 1814140
• Web: www.apexigen.com
• Phone: 650-931-6236
• Fax: N/A
• Employees: 11
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$32.07 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -614.82%
• Return on Assets: -133.30%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.82
• Quick Ratio: 0.82

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.09) per share
• Price / Book: -4.28

Miscellaneous

• Outstanding Shares: 24,862,000
• Free Float: 20,088,000
• Market Cap: $9.57 million
• Optionable: Not Optionable
• Beta: 3.60